These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 28884748)
1. A FISH assay efficiently screens for BRAF gene rearrangements in pancreatic acinar-type neoplasms. Wang L; Basturk O; Wang J; Benayed R; Middha S; Zehir A; Linkov I; Rao M; Aryeequaye R; Cao L; Chmielecki J; Ross J; Stephens PJ; Adsay V; Askan G; Balci S; Klimstra DS Mod Pathol; 2018 Jan; 31(1):132-140. PubMed ID: 28884748 [TBL] [Abstract][Full Text] [Related]
2. RAF1 rearrangements are common in pancreatic acinar cell carcinomas. Prall OWJ; Nastevski V; Xu H; McEvoy CRE; Vissers JHA; Byrne DJ; Takano E; Yerneni S; Ellis S; Green T; Mitchell CA; Murray WK; Scott CL; Grimmond SM; Hofmann O; Papenfuss A; Kee D; Fellowes A; Brown IS; Miller G; Kumarasinghe MP; Perren A; Nahm CB; Mittal A; Samra J; Ahadi M; Fox SB; Chou A; Gill AJ Mod Pathol; 2020 Sep; 33(9):1811-1821. PubMed ID: 32358589 [TBL] [Abstract][Full Text] [Related]
3. BRAF Rearrangements and BRAF V600E Mutations Are Seen in a Subset of Pancreatic Carcinomas With Acinar Differentiation. Ghosh T; Greipp PT; Knutson D; Kloft-Nelson S; Jenkins S; Mounajjed T; Said S; La Rosa S; Vanoli A; Sessa F; Naini BV; Bellizzi A; Zhang L; Kerr SE; Graham RP Arch Pathol Lab Med; 2022 Jul; 146(7):840-845. PubMed ID: 34614142 [TBL] [Abstract][Full Text] [Related]
4. RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas. Chou A; Brown IS; Kumarasinghe MP; Perren A; Riley D; Kim Y; Pajic M; Steinmann A; Rathi V; Jamieson NB; Verheij J; van Roessel S; Nahm CB; Mittal A; Samra J; Gill AJ Mod Pathol; 2020 Apr; 33(4):657-664. PubMed ID: 31558784 [TBL] [Abstract][Full Text] [Related]
5. BRAF gene rearrangements can be identified by FISH studies in pancreatic acinar cell carcinoma. Chou A; Kim Y; Samra JS; Pajic M; Gill AJ Pathology; 2018 Apr; 50(3):345-348. PubMed ID: 29506751 [No Abstract] [Full Text] [Related]
6. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Chmielecki J; Hutchinson KE; Frampton GM; Chalmers ZR; Johnson A; Shi C; Elvin J; Ali SM; Ross JS; Basturk O; Balasubramanian S; Lipson D; Yelensky R; Pao W; Miller VA; Klimstra DS; Stephens PJ Cancer Discov; 2014 Dec; 4(12):1398-405. PubMed ID: 25266736 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569 [TBL] [Abstract][Full Text] [Related]
12. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Ross JS; Wang K; Chmielecki J; Gay L; Johnson A; Chudnovsky J; Yelensky R; Lipson D; Ali SM; Elvin JA; Vergilio JA; Roels S; Miller VA; Nakamura BN; Gray A; Wong MK; Stephens PJ Int J Cancer; 2016 Feb; 138(4):881-90. PubMed ID: 26314551 [TBL] [Abstract][Full Text] [Related]
13. Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets. Chen MF; Yang SR; Tao JJ; Desilets A; Diamond EL; Wilhelm C; Rosen E; Gong Y; Mullaney K; Torrisi J; Young RJ; Somwar R; Yu HA; Kris MG; Riely GJ; Arcila ME; Ladanyi M; Donoghue MTA; Rosen N; Yaeger R; Drilon A; Murciano-Goroff YR; Offin M Clin Cancer Res; 2024 Sep; 30(17):3812-3823. PubMed ID: 38922339 [TBL] [Abstract][Full Text] [Related]
14. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing. Lee YC; Chen JY; Huang CJ; Chen HS; Yang AH; Hang JF Endocr Pathol; 2020 Dec; 31(4):348-358. PubMed ID: 32880785 [TBL] [Abstract][Full Text] [Related]
18. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories. Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865 [TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal stromal tumors with BRAF gene fusions. A report of two cases showing low or absent KIT expression resulting in diagnostic pitfalls. Torrence D; Xie Z; Zhang L; Chi P; Antonescu CR Genes Chromosomes Cancer; 2021 Dec; 60(12):789-795. PubMed ID: 34398495 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing. Wang J; Li R; Li J; Yi Y; Liu X; Chen J; Zhang H; Lu J; Li C; Wu H; Liang Z J Transl Med; 2021 Oct; 19(1):433. PubMed ID: 34657620 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]